Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 66

1.

The neuroblastoma ALK(I1250T) mutation is a kinase-dead RTK in vitro and in vivo.

Schönherr C, Ruuth K, Eriksson T, Yamazaki Y, Ottmann C, Combaret V, Vigny M, Kamaraj S, Palmer RH, Hallberg B.

Transl Oncol. 2011 Aug;4(4):258-65. Epub 2011 Aug 1.

2.

Cell culture and Drosophila model systems define three classes of anaplastic lymphoma kinase mutations in neuroblastoma.

Chand D, Yamazaki Y, Ruuth K, Schönherr C, Martinsson T, Kogner P, Attiyeh EF, Maris J, Morozova O, Marra MA, Ohira M, Nakagawara A, Sandström PE, Palmer RH, Hallberg B.

Dis Model Mech. 2013 Mar;6(2):373-82. doi: 10.1242/dmm.010348. Epub 2012 Oct 25.

3.

Appearance of the novel activating F1174S ALK mutation in neuroblastoma correlates with aggressive tumor progression and unresponsiveness to therapy.

Martinsson T, Eriksson T, Abrahamsson J, Caren H, Hansson M, Kogner P, Kamaraj S, Schönherr C, Weinmar J, Ruuth K, Palmer RH, Hallberg B.

Cancer Res. 2011 Jan 1;71(1):98-105. doi: 10.1158/0008-5472.CAN-10-2366. Epub 2010 Nov 8.

4.

Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684.

Schönherr C, Ruuth K, Yamazaki Y, Eriksson T, Christensen J, Palmer RH, Hallberg B.

Biochem J. 2011 Dec 15;440(3):405-13. doi: 10.1042/BJ20101796.

PMID:
21838707
5.

The ligand Jelly Belly (Jeb) activates the Drosophila Alk RTK to drive PC12 cell differentiation, but is unable to activate the mouse ALK RTK.

Yang HL, Eriksson T, Vernersson E, Vigny M, Hallberg B, Palmer RH.

J Exp Zool B Mol Dev Evol. 2007 May 15;308(3):269-82.

PMID:
17285636
6.

Anaplastic lymphoma kinase activates the small GTPase Rap1 via the Rap1-specific GEF C3G in both neuroblastoma and PC12 cells.

Schönherr C, Yang HL, Vigny M, Palmer RH, Hallberg B.

Oncogene. 2010 May 13;29(19):2817-30. doi: 10.1038/onc.2010.27. Epub 2010 Mar 1.

PMID:
20190816
7.

Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain.

Lee CC, Jia Y, Li N, Sun X, Ng K, Ambing E, Gao MY, Hua S, Chen C, Kim S, Michellys PY, Lesley SA, Harris JL, Spraggon G.

Biochem J. 2010 Sep 15;430(3):425-37. doi: 10.1042/BJ20100609.

PMID:
20632993
8.

Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma.

Janoueix-Lerosey I, Lequin D, Brugières L, Ribeiro A, de Pontual L, Combaret V, Raynal V, Puisieux A, Schleiermacher G, Pierron G, Valteau-Couanet D, Frebourg T, Michon J, Lyonnet S, Amiel J, Delattre O.

Nature. 2008 Oct 16;455(7215):967-70. doi: 10.1038/nature07398.

PMID:
18923523
9.

Anaplastic lymphoma kinase L1198F and G1201E mutations identified in anaplastic thyroid cancer patients are not ligand-independent.

Guan J, Wolfstetter G, Siaw J, Chand D, Hugosson F, Palmer RH, Hallberg B.

Oncotarget. 2017 Feb 14;8(7):11566-11578. doi: 10.18632/oncotarget.14141.

10.

Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients.

Passoni L, Longo L, Collini P, Coluccia AM, Bozzi F, Podda M, Gregorio A, Gambini C, Garaventa A, Pistoia V, Del Grosso F, Tonini GP, Cheng M, Gambacorti-Passerini C, Anichini A, Fossati-Bellani F, Di Nicola M, Luksch R.

Cancer Res. 2009 Sep 15;69(18):7338-46. doi: 10.1158/0008-5472.CAN-08-4419. Epub 2009 Sep 1.

11.

Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma.

Bresler SC, Wood AC, Haglund EA, Courtright J, Belcastro LT, Plegaria JS, Cole K, Toporovskaya Y, Zhao H, Carpenter EL, Christensen JG, Maris JM, Lemmon MA, Mossé YP.

Sci Transl Med. 2011 Nov 9;3(108):108ra114. doi: 10.1126/scitranslmed.3002950.

12.

Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma.

Carpenter EL, Haglund EA, Mace EM, Deng D, Martinez D, Wood AC, Chow AK, Weiser DA, Belcastro LT, Winter C, Bresler SC, Vigny M, Mazot P, Asgharzadeh S, Seeger RC, Zhao H, Guo R, Christensen JG, Orange JS, Pawel BR, Lemmon MA, Mossé YP.

Oncogene. 2012 Nov 15;31(46):4859-67. doi: 10.1038/onc.2011.647. Epub 2012 Jan 23. Erratum in: Oncogene. 2012 Nov 15;31(46):4888. Vigny, M [added]; Mazot, P [added].

13.

The constitutive activity of the ALK mutated at positions F1174 or R1275 impairs receptor trafficking.

Mazot P, Cazes A, Boutterin MC, Figueiredo A, Raynal V, Combaret V, Hallberg B, Palmer RH, Delattre O, Janoueix-Lerosey I, Vigny M.

Oncogene. 2011 Apr 28;30(17):2017-25. doi: 10.1038/onc.2010.595. Epub 2011 Jan 17.

PMID:
21242967
15.

Inhibition of N-linked glycosylation impairs ALK phosphorylation and disrupts pro-survival signaling in neuroblastoma cell lines.

Del Grosso F, De Mariano M, Passoni L, Luksch R, Tonini GP, Longo L.

BMC Cancer. 2011 Dec 22;11:525. doi: 10.1186/1471-2407-11-525.

17.

Characterization of some molecular mechanisms governing autoactivation of the catalytic domain of the anaplastic lymphoma kinase.

Tartari CJ, Gunby RH, Coluccia AM, Sottocornola R, Cimbro B, Scapozza L, Donella-Deana A, Pinna LA, Gambacorti-Passerini C.

J Biol Chem. 2008 Feb 15;283(7):3743-50. Epub 2007 Dec 10.

18.

Oncogenic mutations of ALK kinase in neuroblastoma.

Chen Y, Takita J, Choi YL, Kato M, Ohira M, Sanada M, Wang L, Soda M, Kikuchi A, Igarashi T, Nakagawara A, Hayashi Y, Mano H, Ogawa S.

Nature. 2008 Oct 16;455(7215):971-4. doi: 10.1038/nature07399.

PMID:
18923524
19.

Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene.

Murugan AK, Xing M.

Cancer Res. 2011 Jul 1;71(13):4403-11. doi: 10.1158/0008-5472.CAN-10-4041. Epub 2011 May 19.

20.

Role of the subcellular localization of ALK tyrosine kinase domain in neuronal differentiation of PC12 cells.

Gouzi JY, Moog-Lutz C, Vigny M, Brunet-de Carvalho N.

J Cell Sci. 2005 Dec 15;118(Pt 24):5811-23. Epub 2005 Nov 29.

Supplemental Content

Support Center